ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PHIO
CALC (38) TPST (34) BLRX (46) LTRN (31) ⌘ Pro Terminal →

Phio Pharmaceuticals Corp. (PHIO) — RQD Stock Rating Cockpit

$0.88 +2.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.88

Phio Pharmaceuticals Corp. (PHIO) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $10.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PHIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PHIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.88 (+2.33% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PHIO ranks #550 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PHIO compare to CALC and TPST in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHIO carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and TPST (Tempest Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, PHIO leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PHIO?
▼

Per PHIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533040), Phio Pharmaceuticals Corp. generated $25.8M in revenue (+24.8% YoY), -$8.7M in net income, and -$8.0M in free cash flow against $21.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.88 (+0.23%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (7)Whales (5)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.1% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE PHIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHIO)Realized 20D OHLCV Swing Band: ±12.3%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY PHIO SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$0.94-5.3% Next Q
Q2 (-2Q)
42
Grade D$0.89+0% Next Q
Q3 (-1Q)
40
Grade D$0.89-1.1% Next Q
Current
37
Grade D-$0.88-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PHIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PHIO currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.99) and Max Pain ($0.92) forces dealer call-delta covering toward $4.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PHIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PHIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
37.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$0.88H: $4
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on PHIO

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

10/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like PHIO
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PHIO)

  • ✓Walkthrough of PHIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PHIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.14%📐 HORIZONTAL RANGE
2026-11-03O $0.86H $0.88L $0.86C $0.88VOL 66.7K
RES: $1.33SUP: $0.83SMA50: $0.99SMA200: $1.09
$1.63$1.42$1.20$0.99$0.77RES $1.33SUP $0.83$0.882026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PHIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PHIO Butterfly Map → + Track PHIO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +24.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PHIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PHIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PHIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHIO)

Health Care Rank #550 of 1015 ⚔️ CALC vs PHIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PHIO vs. CALC, TPST, BLRX, LTRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Phio Pharmaceuticals Corp. (PHIO) ranks #550 by composite RQD confidence (37/100, grade D-) and #890 by equity capitalization ($10.0M). Within this direct 5-issuer industry benchmark cohort, PHIO leads on earnings valuation at N/A trailing P/E, while PHIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PHIO at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PHIO ACTIVE
Phio Pharmaceuticals Corp.
D- 37/100 — — -35.0% +2.33% $10.0M Benchmark Subject
CALC
CalciMedica Inc.
D- 38/100 — — -35.0% -4.11% $10.0M /calc-vs-phio →
TPST
Tempest Therapeutics Inc.
E 34/100 — — -35.0% -4.74% $9.9M /tpst-vs-phio →
BLRX
BioLineRx Ltd.
D 46/100 — — — -1.51% $9.9M /blrx-vs-phio →
LTRN
Lantern Pharma Inc.
E 31/100 — — -35.0% -3.15% $9.9M /ltrn-vs-phio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533040 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Phio Pharmaceuticals Corp. (PHIO) reported GAAP revenue of $25.8M (+24.8% vs. FY2024 revenue of $20.7M , and -14.8% cumulative change since FY2023) , GAAP net income of -$8.7M, operating cash flow of -$8.0M, and free cash flow of -$8.0M (-12.3% YoY). On the balance sheet, PHIO closed FY2025 with $21.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $25.8M -$8.7M -$8.0M -$8.0M $21.5M —
FY2024 (FY) 2024-12-31 $20.7M -$7.2M -$7.1M -$7.1M $5.7M —
FY2023 (FY) 2023-12-31 $30.3M -$10.8M -$10.7M -$10.7M — —

3. PHIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PHIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.88 (+2.33% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PHIO ranks #550 in composite RQD confidence.

How does PHIO compare to CALC and TPST in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHIO carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and TPST (Tempest Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, PHIO leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PHIO?

Per PHIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533040), Phio Pharmaceuticals Corp. generated $25.8M in revenue (+24.8% YoY), -$8.7M in net income, and -$8.0M in free cash flow against $21.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PHIO trading relative to its 50-day, 200-day, and 52-week technical levels?

PHIO last traded at $0.88 (+2.33% on volume of 29,820 shares), positioning the stock -11.11% below its 50-day simple moving average ($0.99) and -19.27% below its 200-day simple moving average ($1.09). Across its 52-week range of $0.81 to $4.19, PHIO sits at the 2.1% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($1.00 to $0.99).

Direct Sub-Reports: PHIO RQD Cockpit PHIO 12M Forecast PHIO Earnings & Move PHIO Dividends & DRIP PHIO Insiders & 13F PHIO Whale Options PHIO Profit Sankey PHIO News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PHIO — Phio Pharmaceuticals Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Phio Pharmaceuticals Corp. (PHIO) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.88 (+2.33% 1D, market capitalization $10.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Phio Pharmaceuticals Corp. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The profile describes the company as a Health Care issuer with a market capitalization of $0.0B. Per the news wire, the company's pipeline focus includes a cancer approach designed to help immune cells fight tumors and a skin cancer program.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Phio Pharmaceuticals Corp. (PHIO) reported $25.8M in annual revenue (up from $20.7M in FY2024, +24.8% YoY) and -$8.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($30.3M revenue, -$10.8M net income) through FY2025, PHIO scaled operating cash flow to -$8.0M and free cash flow to -$8.0M, backed by $21.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.81 – $4.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations beyond the profile classification in Health Care and Biotechnology: Pharmaceutical Preparations. A prospective investor should watch whether the company's cash position of $21.0M in FY 2025 is sufficient to fund continued operating losses of -$9.

  • Key Question #1: Can PHIO sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $25.8M and free cash flow of -$8.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PHIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PHIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Phio Pharmaceuticals Corp. (PHIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PHIO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PHIO Bull vs. Bear Conversation Board — What's Your Call at $0.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PHIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PHIO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.14 (+32.6%)
📌 Pinned Debate

Reported cash rose to $21.0M in FY 2025 from $5.4M in FY 2024 while the stock trades near the bottom of its 52-week range.

Long PHIO at $0.86 targeting $1.14. Reported cash rose to $21.0M in FY 2025 from $5.4M in FY 2024 while the stock trades near the bottom of its 52-week range.. Institutional whale score is 5/20 and the risk/reward vs. the $0.81 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@MultipleCompression Shorting a 5/20 institutional whale-flow stock at $0.86 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.72 (-16.3%)
Spot @ $0.86

The company reported no revenue and negative ROIC of -35% with a Piotroski F-Score of 1 out of 9.

I respect the product at Phio Pharmaceuticals Corp., but the stock at $0.86 is a different story. The company reported no revenue and negative ROIC of -35% with a Piotroski F-Score of 1 out of 9.. FCF yield is 0.0% and RQD sits at 37/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE